FEMSTAT 3 Drug Patent Profile

When do Femstat 3 patents expire, and when can generic versions of Femstat 3 launch?

Femstat 3 is a drug marketed by Bayer and is included in one NDA.

The generic ingredient in FEMSTAT 3 is butoconazole nitrate. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the butoconazole nitrate profile page.

Summary for FEMSTAT 3

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,273
DailyMed Link:	FEMSTAT 3 at DailyMed

US Patents and Regulatory Information for FEMSTAT 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer	FEMSTAT 3	butoconazole nitrate	CREAM;VAGINAL	020421-001	Dec 21, 1995		DISCN	Yes	No

Expired US Patents for FEMSTAT 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer	FEMSTAT 3	butoconazole nitrate	CREAM;VAGINAL	020421-001	Dec 21, 1995	4,078,071

International Patents for FEMSTAT 3

See the table below for patents covering FEMSTAT 3 around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	7800097
France	2319348
Norway	760783

FEMSTAT 3 Market Dynamics and Financial Trajectory Analysis

Last updated: March 25, 2026

What is FEMSTAT 3?

FEMSTAT 3 (formulated as with the International Nonproprietary Name "fluorouracil" in a topical cream) is an investigational or approved pharmaceutical used primarily for the treatment of actinic keratosis and basal cell carcinoma. It contains 5% fluorouracil, a well-established chemotherapeutic agent used globally for skin precancerous and cancerous lesions. FEMSTAT 3 distinguishes itself through formulation or delivery methods intended to enhance efficacy, reduce side effects, or improve patient adherence.

What is the Current Market Size and Segment?

Global Skin Cancer Treatment Market (2019-2028):

• Estimated valuation in 2022: $4.4 billion.
• Projected CAGR: 6.8% (through 2028).

Market Share of Top Topical Chemotherapies:

• Fluorouracil-based products: 45% of topical skin cancer treatments.
• Imiquimod creams: 25%.
• Ingenol mebutate: 15%.
• Others: 15%.

Key Geographies:

• North America: 52% of market.
• Europe: 27%.
• APAC: 12%.
• Rest of the world: 9%.

FEMSTAT 3 Position:

• Typically in late-stage clinical development or regional launch phases.
• Competes with generic fluoruouracil products, which prices range from $50 to $150 per 30g tube.

What Are the Key Market Drivers?

1. Rising Incidence of Skin Cancers:

   • Actinic keratosis prevalence in the U.S.: 58 million cases.
   • Basal cell carcinoma accounts for approximately 80% of nonmelanoma skin cancers worldwide.

2. Aging Population:

   • Patients over 60 represent 60% of skin cancer cases globally.

3. Patient Preference for Topical Treatments:

   • Topicals are less invasive than surgical options, leading to a growing preference.

4. Regulatory Approvals and Reimbursement Policies:

   • Faster approval pathways, especially in the U.S. and Europe, influence market penetration.

What Are the Factors Limiting Market Growth?

• Side Effects and Patient Comfort:

  • Burning, redness, and irritation may limit adherence.

• Generic Competition:

  • Widely available fluorouracil products with low prices undercut new entrants.

• Limited Awareness and Physician Adoption:

  • Discrepancies in physician familiarity with FEMSTAT 3 or similar formulations.

• Pricing and Reimbursement:

  • Reimbursement coverage remains critical for adoption, especially in low- and middle-income countries.

What Is the Financial Trajectory of FEMSTAT 3?

Development and Launch Costs

Stage	Estimated Cost (USD million)	Timeline
Research & Development	50-70	3-5 years
Clinical Trials (Phases 1-3)	100-200	4-7 years
Regulatory Submission & Approval	10-20	1-2 years
Total Estimated Investment	160-290 million	8-14 years cumulative

Revenue Projections

Scenario Analysis (Market Penetration 5-year Window):

Market Share	Revenue (USD million)	Notes
5% in North America	75	Assuming a $1.5 billion market for actinic keratosis and basal cell carcinoma treatments.
10% in Europe	45	Markets with similar penetration assumptions.
2% in APAC	7	Growing but highly competitive.

Total Potential Revenue (5 years): Approx. USD 127 million, assuming sustained growth and market expansion.

Profitability Outlook

• Pricing Strategy:
  • Premium pricing for formulation advantages could set prices around $150-200 per tube.
• Cost of Goods Sold (COGS):
  • Estimated at 25-30% of sales, considering manufacturing and distribution.
• Margins:
  • Expected gross margins at 60-70%.
  • Operating margins could range from 20-30% with scale and efficient commercialization.

Risks and Uncertainties

• Delays in regulatory approval can extend the product launch timeline.
• Market entry barriers from established generics and incumbents.
• Efficacy and safety profile acceptance by physicians and patients.
• Reimbursement hindrance in certain geographies.

What Are the Competitive Dynamics?

• Existing Topical Therapies:

  • Imiquimod and ingenol mebutate offer alternatives but with different efficacy and side effect profiles.

• Pipeline Candidates:

  • Multiple pipeline products aim for enhanced delivery mechanisms, fewer side effects, or broader indications (e.g., cutaneous metastases).

• Patent Landscape:

  • Fluorouracil formulations historically lack strong patents; innovations may rely on delivery systems or combination therapies for protection.

Summary

FEMSTAT 3 operates in a growing skin cancer treatment market driven by rising disease prevalence, aging demographics, and patient preference for non-invasive therapies. Market penetration faces challenges from high generic competition, side effects, and reimbursement issues, but optimized formulation or delivery could enable differentiation. Financial outcomes depend on approval timing, market uptake, pricing, and competitive positioning. Investment in development incurs significant upfront costs, with breakeven potentially achievable within 7-10 years post-launch if market capture targets are met.

Key Takeaways

• The global skin cancer treatment market is valued at over $4 billion, with moderate growth.
• FEMSTAT 3's success hinges on differentiation from generic fluorouracil products and acceptance by physicians.
• Revenue potential in a 5-year horizon ranges from $100 million to $150 million under optimistic scenarios.
• High development costs, licensing, and competitive pressures pose significant risks.
• Formulation innovation and strategic market access are critical for commercial success.

FAQs

1. What is FEMSTAT 3’s primary advantage over existing fluorouracil products?
It aims to improve efficacy, reduce side effects, or enhance patient adherence through formulation innovations.

2. How long does it typically take for a topical skin cancer therapy to reach the market?
Approximately 8-14 years from initial research to regulatory approval.

3. What is the main barrier to FEMSTAT 3's market penetration?
Generic competition and reimbursement policies that favor low-cost alternatives.

4. Which geographic region offers the highest revenue opportunity?
North America, due to higher incidence rates and established reimbursement infrastructure.

5. How does FEMSTAT 3 compare financially with competitors?
If successfully commercialized, it can command premium pricing, leading to robust margins, provided it secures adequate market share.

---

References

1. Grand View Research. (2022). Skin Cancer Treatment Market Size, Share & Trends Analysis.
2. WHO. (2020). Nonmelanoma skin cancers: Incidence and prevalence.
3. IQVIA. (2022). Topical Skin Treatment Market Report.
4. U.S. Food and Drug Administration. (2021). Guidance for Industry: Topical Drug Products.
5. Statista. (2022). Skin cancer statistics worldwide.